"He stressed that the loan WOULD NOT becoming due before the top line BETonMACE data comes out...."

That's a bold statement in my opinion. I'd still take it with a grain of salt until more concrete info is disclosed publicly. Safe harbor, yadda yadda yadda. Now, if the SSRA comes out soon confirming that we've hit 188/250 events and that no more patients, events, time and money are going to be needed than already expected in the current trial design, then it's a different story. Consistent with this, GAC noted "Don reiterated that top line data should be out by the end of year." By "should" this likely means barring any changes to current trial design. Even if Don thinks of"BETonMACE as being "properly powered", we will need to wait for the official word from the SSRA interim analysis for this judgement.

"I don't recall the exact words or turns of phrase, but my understanding was this.....When the top line data comes out Don seems to be expecting to do a more traditional equity raise with the PPS substantially higher, and I "think" he mentioned a figure somewhere around $5....and then qualified that by saying that it could be even higher."

Looking at the market cap and share price right now, CAD $5 (~USD $4) per share would put us around CAD $900 million (~USD $700 million) market cap. If we get top-line data that this small, Canadian biotech has just passed its Phase 3 CVOT trial achieving its primary outcome of reducing 3-point MACE, then I would expect the "it could be even higher." We probably won't know the exact RRR until much later, but still if top-line data is positive I'd expect much higher. 

"He said that trials for CKD and Fabry's would commence when financed, and that they'd be announced when the financing happens." 

That is still not clear if these trials will be funded by the imminent Third Eye $30 M loan, or a different financing. Hopefully the former. I think we'd all agree they need to get these other trials underway. It would be great if they could start the kidney trial before the ERA-EDTA symposium later this month.

"Zenith...."

I'll move my Zenith comments over to the Zenith board. But in short......if truly Zenith is in the process of getting bought out, has stellar trial data proving improved progression free survival/PSA response beyond enzalutamide alone standard of care, and has a forthcoming publication.....then that's great. But Zenith has kept their cards close to their chest so I'm skeptical, but also cautiously optimistic (is that possible?)

Thanks again for all in info GAC/Led,

BDAZ